These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 27889591)

  • 1. Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis.
    Vouri SM; Kebodeaux CD; Stranges PM; Teshome BF
    Arch Gerontol Geriatr; 2017; 69():77-96. PubMed ID: 27889591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative Risk of Adverse Events and Treatment Discontinuations Between Older and Non-Older Adults Treated with Antimuscarinics for Overactive Bladder: A Systematic Review and Meta-Analysis.
    Usmani SA; Reckenberg K; Johnson O; Stranges PM; Teshome BF; Kebodeaux CD; Vouri SM
    Drugs Aging; 2019 Jul; 36(7):639-645. PubMed ID: 31054113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-analysis.
    Lozano-Ortega G; Walker DR; Johnston K; Mickle A; Harrigan S; Rogula B; Kristy RM; Hairston JC; Schermer CR
    Drugs Aging; 2020 Nov; 37(11):801-816. PubMed ID: 32960422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.
    Wagg A; Nitti VW; Kelleher C; Castro-Diaz D; Siddiqui E; Berner T
    Curr Med Res Opin; 2016; 32(4):621-38. PubMed ID: 26828974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach.
    Kessler TM; Bachmann LM; Minder C; Löhrer D; Umbehr M; Schünemann HJ; Kessels AG
    PLoS One; 2011 Feb; 6(2):e16718. PubMed ID: 21373193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
    Maman K; Aballea S; Nazir J; Desroziers K; Neine ME; Siddiqui E; Odeyemi I; Hakimi Z
    Eur Urol; 2014 Apr; 65(4):755-65. PubMed ID: 24275310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.
    Chapple CR; Khullar V; Gabriel Z; Muston D; Bitoun CE; Weinstein D
    Eur Urol; 2008 Sep; 54(3):543-62. PubMed ID: 18599186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.
    Nazir J; Kelleher C; Aballéa S; Maman K; Hakimi Z; Mankowski C; Odeyemi I
    Neurourol Urodyn; 2018 Mar; 37(3):986-996. PubMed ID: 29140559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses.
    Buser N; Ivic S; Kessler TM; Kessels AG; Bachmann LM
    Eur Urol; 2012 Dec; 62(6):1040-60. PubMed ID: 22999811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Antimuscarinic Drugs on Cognitive Functions in the Management of Overactive Bladder in Elderly.
    Rangganata E; Widia F; Rahardjo HE
    Acta Med Indones; 2020 Jul; 52(3):255-263. PubMed ID: 33020336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events?
    Paquette A; Gou P; Tannenbaum C
    J Am Geriatr Soc; 2011 Jul; 59(7):1332-9. PubMed ID: 21718264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What Are the Short-term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the European Association of Urology, Female Non-neurogenic Lower Urinary Tract Symptoms Guidelines Panel.
    Farag F; Sakalis VI; Arteaga SM; Sihra N; Karavitakis M; Arlandis S; Bø K; Cobussen-Boekhorst H; Costantini E; de Heide M; Groen J; Peyronnet B; Phé V; van Poelgeest-Pomfret ML; van den Bos TWL; van der Vaart H; Harding CK; Carmela Lapitan M; Imran Omar M; Nambiar AK
    Eur Urol; 2023 Sep; 84(3):302-312. PubMed ID: 37331921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study.
    Kachru N; Holmes HM; Johnson ML; Chen H; Aparasu RR
    Curr Med Res Opin; 2021 Aug; 37(8):1303-1313. PubMed ID: 33890538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men.
    De Nunzio C; Brucker B; Bschleipfer T; Cornu JN; Drake MJ; Fusco F; Gravas S; Oelke M; Peyronnet B; Tutolo M; van Koeveringe G; Madersbacher S
    Eur Urol; 2021 Apr; 79(4):492-504. PubMed ID: 33402296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Mostafaei H; Salehi-Pourmehr H; Jilch S; Carlin GL; Mori K; Quhal F; Pradere B; Grossmann NC; Laukhtina E; Schuettfort VM; Aydh A; Sari Motlagh R; König F; Roehrborn CG; Katayama S; Rajwa P; Hajebrahimi S; Shariat SF
    Eur Urol Focus; 2022 Jul; 8(4):1072-1089. PubMed ID: 34563481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis.
    Yang N; Wu Q; Xu F; Zhang X
    J Int Med Res; 2021 Sep; 49(9):3000605211042994. PubMed ID: 34510960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticholinergic burden in the Japanese elderly population: Use of antimuscarinic medications for overactive bladder patients.
    Yoshida M; Kato D; Nishimura T; Van Schyndle J; Uno S; Kimura T
    Int J Urol; 2018 Oct; 25(10):855-862. PubMed ID: 30069973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
    Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
    World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.
    Aparasu RR; Sura S; Earla JR; Shiozawa A; Ng DB; Schermer CR
    Adv Ther; 2020 Aug; 37(8):3584-3605. PubMed ID: 32638205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.